BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:PG-102 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of PG-102\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07677891-257@assetmemo.bio
DTSTAMP:20261121T004536Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:PG-102: Phase 2 readout est. (NCT07677891)
DESCRIPTION:PG-102\, phase 2\, Type 2 Diabetes.\nStudy: Phase II Study of S
 witching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus\nEst
 imated primary completion: May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pg-102#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07677891
URL:https://assetmemo.bio/drug/pg-102#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
